PHM1N Stock Chart & Stats
$1780.91
$0.00(0.00%)
At close: 4:00 PM EDT
$1780.91
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,780.91 - $1,780.91
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$25.98B
Enterprise Value$1.18B
Total Cash (Recent Filing)$168.88M
Total Debt (Recent Filing)$45.84M
Price to Earnings (P/E)21.2
Beta0.09
Next Earnings
Mar 01, 2027EPS Estimate
20.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.26
Shares Outstanding18,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,081.95Price Target Upside16.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)39.12
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityVery high gross and net margins indicate that Pharma Mar’s oncology portfolio currently converts revenue into substantial earnings. This profitability provides internal funding capacity for research and commercialization while offering a stronger buffer against operating-cost pressure over the next several quarters.
Low Financial LeverageThe conservatively financed balance sheet limits the burden of debt service and preserves financial flexibility. A solid equity base gives Pharma Mar more capacity to support development programs, absorb earnings variability, and allocate capital without relying heavily on external financing.
Positive Cash ConversionRecent operating and free cash flow show that reported profits are translating into cash at a generally healthy rate. This strengthens the company’s ability to fund ongoing operations and pipeline investment internally, reducing dependence on capital markets during the coming months.
Bears Say
Inconsistent Revenue GrowthThe latest revenue decline shows that Pharma Mar’s commercial growth has not yet become consistently durable. Uneven top-line performance can make future earnings less predictable and may constrain the pace at which the company can reinvest in oncology products and its development pipeline.
Volatile Cash GenerationAlthough current cash generation is positive, the history of negative free cash flow and the latest decline demonstrate meaningful variability. Such fluctuations can complicate budgeting for research and commercialization, particularly when product or partnership receipts change between periods.
Uneven Earnings ProfileThe sharp movement from near-zero profitability and negative EBIT to strong earnings, followed by TTM moderation, indicates that results remain sensitive to operating conditions. This reduces confidence that current margins and returns will persist evenly across future reporting periods.
Pharma Mar SA News
PHM1N FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was $1780.91 and its highest was $1780.91 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is $25.98B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Mar 01, 2027 which is in 122 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Oct 29, 2026. The company reported $9.932 earnings per share for the quarter, beating the consensus estimate of $2.684 by $7.248.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA does not currently pay dividends.
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 20.77.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of $9.932 in its last earnings report, beating expectations of $2.684. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in MX:PHM1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,081.95 (16.90% Upside)
$2,081.95 (16.90% Upside)
Blogger Sentiment
Neutral
MX:PHM1N Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $702.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.23%
12-Months-Change
Fundamentals
Return on Equity
23.64%
Trailing 12-Months
Asset Growth
10.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
PHM1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all MX:PHM1N earnings summariesPHM1N Stock 12 Month Forecast
Average Price Target
$2,081.95
▲(16.90% Upside)